MBX Biosciences, Inc. Common Stock (MBX) — Net Asset Quality Index
MBX Biosciences, Inc. Common Stock (MBX) has a Net Asset Quality Index of 96.7% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $452.70 Million minus total liabilities of $14.95 Million yields net assets of $437.76 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check MBX financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
MBX Biosciences, Inc. Common Stock Net Asset Quality Index Over Time (2022–2025)
This chart shows how MBX Biosciences, Inc. Common Stock's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 96.7%, representing net assets of $437.76 Million against total assets of $452.70 Million USD. See MBX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for MBX Biosciences, Inc. Common Stock from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see MBX market cap overview.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.9% | $369.22 Million | $385.14 Million | $15.92 Million | ▼ 0.0 pp |
| 2024 | 95.9% | $257.44 Million | $268.54 Million | $11.09 Million | ▲ +182.0 pp |
| 2023 | -86.1% | $-72.47 Million | $84.18 Million | $156.65 Million | ▲ +8.4 pp |
| 2022 | -94.5% | $-42.60 Million | $45.09 Million | $87.70 Million | — |